Literature DB >> 12505259

Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature.

Yi Kong Keung1, Michael Beaty, William Steward, Bethy Jackle, Mark Pettnati.   

Abstract

Chronic myelocytic leukemia (CML) is a chronic myeloproliferative disorder characterized by cytogenetic or molecular evidence of Philadelphia (Ph) chromosome, t(9;22)(q34;q11). Mild to moderate eosinophilia is commonly seen in CML. However, eosinophilia as a dominant feature of CML is extremely rare. We describe a case of Ph(-) CML with eosinophilia. Loeffler endocarditis, and t(9;12)(q34;p13) that resulted in an ETV6-ABL gene rearrangement/fusion identified to the best of our knowledge, for the first time by using commercially available fluorescence in situ hybridization probes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12505259     DOI: 10.1016/s0165-4608(02)00609-x

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  14 in total

1.  ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition.

Authors:  Fabiana Perna; Omar Abdel-Wahab; Ross L Levine; Suresh C Jhanwar; Kazunori Imada; Stephen D Nimer
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

2.  Bcr-Abl activates the AKT/Fox O3 signalling pathway to restrict transforming growth factor-beta-mediated cytostatic signals.

Authors:  Azeddine Atfi; Lucile Abécassis; Marie-Francoise Bourgeade
Journal:  EMBO Rep       Date:  2005-10       Impact factor: 8.807

3.  A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.

Authors:  Ryan P Million; Nari Harakawa; Sergei Roumiantsev; Lyuba Varticovski; Richard A Van Etten
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

Review 4.  Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis.

Authors:  Ayalew Tefferi; Animesh Pardanani
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

5.  Characterization of leukemias with ETV6-ABL1 fusion.

Authors:  Marketa Zaliova; Anthony V Moorman; Giovanni Cazzaniga; Martin Stanulla; Richard C Harvey; Kathryn G Roberts; Sue L Heatley; Mignon L Loh; Marina Konopleva; I-Ming Chen; Olga Zimmermannova; Claire Schwab; Owen Smith; Marie-Joelle Mozziconacci; Christian Chabannon; Myungshin Kim; J H Frederik Falkenburg; Alice Norton; Karen Marshall; Oskar A Haas; Julia Starkova; Jan Stuchly; Stephen P Hunger; Deborah White; Charles G Mullighan; Cheryl L Willman; Jan Stary; Jan Trka; Jan Zuna
Journal:  Haematologica       Date:  2016-05-26       Impact factor: 9.941

Review 6.  Eosinophilic disorders in various diseases.

Authors:  Jocelyn Celestin; Marianne Frieri
Journal:  Curr Allergy Asthma Rep       Date:  2012-02       Impact factor: 4.919

Review 7.  Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.

Authors:  Ashleigh R Poh; Robert J J O'Donoghue; Matthias Ernst
Journal:  Oncotarget       Date:  2015-06-30

8.  Myeloproliferative neoplasm with ETV6-ABL1 fusion: a case report and literature review.

Authors:  Katya Gancheva; Andres Virchis; Julie Howard-Reeves; Nick Cp Cross; Diana Brazma; Colin Grace; Paul Kotzampaltiris; Fedra Partheniou; Elisabeth Nacheva
Journal:  Mol Cytogenet       Date:  2013-09-20       Impact factor: 2.009

9.  An ETV6-ABL1 fusion in a patient with chronic myeloproliferative neoplasm: Initial response to Imatinib followed by rapid transformation into ALL.

Authors:  Purvi M Kakadia; Ralf Schmidmaier; Andreas Völkl; Irene Schneider; Natalia Huk; Stephanie Schneider; Gerda Panzner; Ulrike Neidel; Barbara Fritz; Karsten Spiekermann; Stefan K Bohlander
Journal:  Leuk Res Rep       Date:  2016-10-14

Review 10.  Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Authors:  Ayalew Tefferi
Journal:  J Cell Mol Med       Date:  2008-10-23       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.